{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:47:45Z","timestamp":1777420065811,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"national center for advancing translational sciences","doi-asserted-by":"publisher","award":["UL1TR001998"],"award-info":[{"award-number":["UL1TR001998"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Additional therapies for hepatic encephalopathy (HE) treatment are warranted. There are data evaluating the use of zinc for HE; however, clinical outcomes, specifically in the United States, are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To compare 30-day and 1-year all-cause readmission rates in patients with cirrhosis complicated by HE on lactulose and rifaximin to those on lactulose, rifaximin, and zinc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study included patients admitted with documented cirrhosis and home medications of lactulose and rifaximin, with or without zinc. Patients were stratified into 2 groups: those receiving lactulose and rifaximin for HE (control) and those receiving lactulose, rifaximin, and zinc for HE (treatment). The primary outcomes were 30-day and 1-year all-cause readmission rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>One-hundred fifty-seven patients were included (102 in control group, 55 in treatment group). Regarding 30-day and 1-year all-cause readmission rates, there was no difference between the control and treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>This is the first study conducted in the United States evaluating zinc for HE treatment. Zinc did not impact 30-day or 1-year all-cause readmission rates. Further studies are warranted to evaluate the potential benefit of zinc for HE, possibly in correlation with Model for End-stage Liver Disease-Sodium (MELD-Na) scores.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221134283","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T04:57:27Z","timestamp":1668142647000},"page":"899-906","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8150-0610","authenticated-orcid":false,"given":"Megan Kunka","family":"Fritz","sequence":"first","affiliation":[{"name":"Department of Pharmacy, UK HealthCare, Lexington, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-9989","authenticated-orcid":false,"given":"Anthony A.","family":"Mangino","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Kentucky, Lexington, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor V.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UK HealthCare, Lexington, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Tyler","family":"Pitcock","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UK HealthCare, Lexington, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-3781","authenticated-orcid":false,"given":"Adam J.","family":"Dugan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Kentucky, Lexington, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kishore","family":"Karri","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, UK HealthCare, Lexington, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Yarra","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, UK HealthCare, Lexington, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27210."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016645826."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1600561."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.4746."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2014.04.018."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-12-74."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12937-019-0461-3."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2021.22.9.2879."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2021.06.007."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.063."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1877148."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221134283","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221134283","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221134283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:12:53Z","timestamp":1777374773000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221134283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1177\/10600280221134283"],"URL":"https:\/\/doi.org\/10.1177\/10600280221134283","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]}}}